Target- |
Mechanism- |
Active Org.- |
Originator Org.- |
Active Indication- |
|
Drug Highest PhaseSuspended |
First Approval Ctry. / Loc.- |
First Approval Date- |
纳武利尤单抗联合伊匹木单抗对比化疗治疗一线胸膜间皮瘤
[Translation] Nivolumab combined with ipilimumab versus chemotherapy in first-line pleural mesothelioma
主要目的:评估纳武利尤单抗联合伊匹木单抗与培美曲塞联合顺铂或卡铂方案作为一线疗法治疗中国不可切除恶性胸膜间皮瘤参与者的OS。
次要目的:评估纳武利尤单抗联合伊匹木单抗和培美曲塞联合顺铂或卡铂作为一线疗法治疗中国不可切除胸膜间皮瘤参与者的ORR(通过研究者确定),PFS,安全性和耐受性。
[Translation] Main objective: To evaluate OS in Chinese participants with unresectable malignant pleural mesothelioma with nivolumab plus ipilimumab versus pemetrexed plus cisplatin or carboplatin regimens as first-line therapy.
Secondary objectives: To assess ORR (as determined by investigator), PFS, nivolumab plus ipilimumab and pemetrexed plus cisplatin or carboplatin as first-line therapy in Chinese participants with unresectable pleural mesothelioma , safety and tolerability.
100 Clinical Results associated with Bristol-Myers Squibb Holdings Pharma LLC
0 Patents (Medical) associated with Bristol-Myers Squibb Holdings Pharma LLC
100 Deals associated with Bristol-Myers Squibb Holdings Pharma LLC
100 Translational Medicine associated with Bristol-Myers Squibb Holdings Pharma LLC